Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 4
2005 6
2006 5
2007 8
2008 9
2009 7
2010 11
2011 6
2012 5
2013 7
2014 10
2015 5
2016 9
2017 12
2018 10
2019 10
2020 14
2021 14
2022 5
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B, Xu-Vuilard A, Jouinot A, Puisset F, Combarel D, Huillard O, Le Louedec F, Thomas F, Teixeira M, Flippot R, Mourey L, Albiges L, Pudlarz T, Joly C, Tournigand C, Chauvin J, Puszkiel A, Chatelut E, Decleves X, Vidal M, Goldwasser F, Oudard S, Medioni J, Vano YA. Blanchet B, et al. Among authors: chatelut e. Br J Cancer. 2024 Apr;130(6):961-969. doi: 10.1038/s41416-024-02585-y. Epub 2024 Jan 25. Br J Cancer. 2024. PMID: 38272963
Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.
Loison G, Bouges Le Royer H, Marsili S, Brice A, Vintejoux J, Yakoubi M, Sirgue H, Chatelut E, Etienne-Grimaldi MC, Thomas F; on behalf of the GPCO-UNICANCER group. Loison G, et al. Among authors: chatelut e. Clin Chem Lab Med. 2024 Jan 11;62(6):e129-e131. doi: 10.1515/cclm-2023-1096. Print 2024 May 27. Clin Chem Lab Med. 2024. PMID: 38198224 Free article. No abstract available.
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer.
Lambert M, Alonso M, Munzer C, Zimoch MC, Malard L, Gambart M, Castex MP, Martins C, Pasquet M, Chatelut E. Lambert M, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 2024 Apr;93(4):393-395. doi: 10.1007/s00280-023-04597-6. Epub 2023 Oct 3. Cancer Chemother Pharmacol. 2024. PMID: 37789166
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.
Valentin T, Lambert M, Chaltiel L, Allal B, Mseddi M, Yakoubi M, Chevreau C, Toulmonde M, Firmin N, Filleron T, Chatelut E. Valentin T, et al. Among authors: chatelut e. Eur J Pharm Sci. 2023 Jun 1;185:106420. doi: 10.1016/j.ejps.2023.106420. Epub 2023 Mar 5. Eur J Pharm Sci. 2023. PMID: 36882147 Free article.
Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.
Puisset F, Le Louedec F, Dalenc F, Verguet L, De Maio E, Lacaze JL, Montastruc M, Ung M, Vinson C, Perriat S, Pacher S, Chatelut E, Koning MW. Puisset F, et al. Among authors: chatelut e. Br J Clin Pharmacol. 2023 Jul;89(7):2283-2294. doi: 10.1111/bcp.15702. Epub 2023 Mar 20. Br J Clin Pharmacol. 2023. PMID: 36854898
153 results